文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

利用预靶向策略优化基于单域抗体的放射性药物的治疗指数

Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting.
PubMed 文献 · J Nucl Med · 2024-10-01

研究采用点击化学预靶向策略,以成纤维细胞激活蛋白α(FAP)靶向单域抗体4AH29为载体,在健康小鼠和U87MG(FAP+)异种移植瘤中优化预靶向参数,并在胰腺导管腺癌患者来源异种移植(PDX)模型中开展177Lu治疗性核素试验。结果显示,注射200微克4AH29-TCO、8小时后注射[177Lu]Lu-DOTA-PEG7-四嗪可获得最高肾脏治疗指数(2.0±0.4),较常规[177Lu]Lu-DOTA-4AH29(0.4±0.1)高5倍;预靶向高活度方案较常规方案延长生存,且未观察到常规组出现的系膜扩张。

要点

  • 注射200微克4AH29-TCO、8小时后注射[177Lu]Lu-DOTA-PEG7-四嗪,肾脏治疗指数最高(2.0±0.4),较常规方案(0.4±0.1)高5倍。
  • 预靶向高活度方案(3×88 MBq,每周1次共3周)较常规方案(3×37 MBq,每周1次共3周)和载体对照延长PDAC PDX小鼠生存。
  • 常规组10只小鼠中7只报告系膜扩张,预靶向组未观察到。

核心结论

  • 本研究验证预靶向可减轻单域抗体的肾脏滞留,在早期时间点未观察到治疗方案相关的形态学改变。
  • 基于点击化学的预靶向放射性核素治疗能够缓解生物载体固有药代动力学特征相关毒性,值得临床转化。
  • 缺乏具有广泛间质和高FAP表达的癌症相关成纤维细胞的代表性动物模型,导致即使注射高活度,PDAC PDX的平均肿瘤吸收剂量仍低,生存获益有限。

研究设计与样本

  • 在健康小鼠和U87MG(FAP+)异种移植瘤中优化预靶向关键参数(单域抗体注射质量与间隔时间)。
  • 在胰腺导管腺癌患者来源异种移植(PDAC PDX)模型中开展预靶向治疗性核素试验作为先导研究。

主要发现

  • 用反式环辛烯(TCO)修饰4AH29未改变单域抗体的药代动力学特征。
  • 注射200微克4AH29-TCO、8小时后注射[177Lu]Lu-DOTA-PEG7-四嗪,肾脏治疗指数最高(2.0±0.4),较[177Lu]Lu-DOTA-4AH29(0.4±0.1)高5倍。
  • PDAC PDX模型中,免疫组织化学和PET/CT成像均验证肿瘤微环境FAP表达。
  • 预靶向高活度组(4AH29-TCO+[177Lu]Lu-DOTA-PEG7-四嗪;3×88 MBq,每周1次共3周)小鼠生存较载体对照组和常规治疗组([177Lu]Lu-DOTA-4AH29;3×37 MBq,每周1次共3周)延长。
  • 常规组10只小鼠中7只报告系膜扩张,提示治疗相关肾脏形态学改变;预靶向组未观察到。

临床怎么用

  • 作者认为,基于点击化学的预靶向放射性核素治疗能够缓解生物载体固有药代动力学相关毒性,值得临床转化。

局限性

  • 缺乏具有广泛间质和高FAP表达的癌症相关成纤维细胞的代表性动物模型,导致即使注射高活度,PDAC PDX的平均肿瘤吸收剂量仍低,生存获益有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Single-domain antibodies (sdAbs) demonstrate favorable pharmacokinetic profiles for molecular imaging applications. However, their renal excretion and retention are obstacles for applications in targeted radionuclide therapy (TRT). Methods: Using a click-chemistry-based pretargeting approach, we aimed to reduce kidney retention of a fibroblast activation protein α (FAP)-targeted sdAb, 4AH29, for 177Lu-TRT. Key pretargeting parameters (sdAb-injected mass and lag time) were optimized in healthy mice and U87MG (FAP+) xenografts. A TRT study in a pancreatic ductal adenocarcinoma (PDAC) patient-derived xenograft (PDX) model was performed as a pilot study for sdAb-based pretargeting applications. Results: Modification of 4AH29 with trans-cyclooctene (TCO) moieties did not modify the sdAb pharmacokinetic profile. A 200-µg injected mass of 4AH29-TCO and an 8-h lag time for the injection of [177Lu]Lu-DOTA-PEG7-tetrazine resulted in the highest kidney therapeutic index (2.0 ± 0.4), which was 5-fold higher than that of [177Lu]Lu-DOTA-4AH29 (0.4 ± 0.1). FAP expression in the tumor microenvironment was validated in a PDAC PDX model with both immunohistochemistry and PET/CT imaging. Mice treated with the pretargeting high-activity approach (4AH29-TCO + [177Lu]Lu-DOTA-PEG7-tetrazine; 3 × 88 MBq, 1 injection per week for 3 wk) demonstrated prolonged survival compared with the vehicle control and conventionally treated ([177Lu]Lu-DOTA-4AH29; 3 × 37 MBq, 1 injection per week for 3 wk) mice. Mesangial expansion was reported in 7 of 10 mice in the conventional cohort, suggesting treatment-related kidney morphologic changes, but was not observed in the pretargeting cohort. Conclusion: This study validates pretargeting to mitigate sdAbs' kidney retention with no observation of morphologic changes on therapy regimen at early time points. Clinical translation of click-chemistry-based pre-TRT is warranted on the basis of its ability to alleviate toxicities related to biovectors' intrinsic pharmacokinetic profiles. The absence of representative animal models with extensive stroma and high FAP expression on cancer-associated fibroblasts led to a low mean tumor-absorbed dose even with high injected activity and consequently to modest survival benefit in this PDAC PDX.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Poty S, Ordas L, Dekempeneer Y, et al. Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting. J Nucl Med. 2024. PMID: 39266288. doi:10.2967/jnumed.124.267624

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。